C-MET & HGF Inhibitors Market Size, Share, Growth and Industry analysis, By Type (Cabozantinib, Crizotinib), By Application (Hospital, Drug Store) and Regional Forecast to 2034

• 

  Download Free Sample to learn more about this report

C-MET & HGF INHIBITORS MARKET OVERVIEW

The global c-met & hgf inhibitors market is valued at about USD 6.65 Billion in 2026 and is projected to reach USD 49.13 Billion by 2035. It grows at a compound annual growth rate (CAGR) of around 24.89% from 2026 to 2035.

The C-MET & HGF Inhibitors Market is driven by the increasing prevalence of MET gene alterations observed in approximately 3%–4% of non-small cell lung cancer (NSCLC) cases and 5%–10% of papillary renal cell carcinoma cases worldwide. Globally, lung cancer accounts for nearly 2.2 million new cases annually, with MET exon 14 skipping mutations identified in around 70,000–90,000 patients per year. Over 120 clinical trials evaluating c-MET & HGF inhibitors were active across 25+ countries in 2024. The C-MET & HGF Inhibitors Market Size is supported by targeted oncology drug penetration, which exceeded 60% of newly approved oncology therapies between 2020 and 2024.

In the United States, approximately 238,000 new lung cancer cases were diagnosed in 2023, with MET exon 14 alterations present in nearly 4% of these patients, equating to about 9,500 cases annually. The FDA approved more than 5 targeted therapies addressing MET pathways between 2020 and 2024. Around 65% of advanced NSCLC patients in the U.S. undergo molecular testing, improving the adoption of c-MET & HGF inhibitors. Over 40 oncology centers across 20 states are actively involved in MET-targeted clinical trials, reinforcing the C-MET & HGF Inhibitors Market Growth in the U.S. healthcare ecosystem.

KEY FINDINGS

LATEST TRENDS

The C-MET & HGF Inhibitors Market Trends indicate a sharp rise in precision oncology adoption, with over 75% of tertiary cancer centers integrating next-generation sequencing panels in 2024. MET amplification testing increased by 48% globally between 2021 and 2024. Combination regimens involving MET inhibitors and immune checkpoint inhibitors accounted for nearly 52% of ongoing Phase II and Phase III trials in 2024. Over 30 new clinical programs focusing on dual inhibition strategies were initiated across 18 countries.

Companion diagnostics integration expanded by 35% in 3 years, and over 20 regulatory designations for MET-targeted therapies were granted globally. The C-MET & HGF Inhibitors Market Research Report highlights that 62% of oncologists prefer targeted therapy over chemotherapy for MET-driven cancers. Additionally, real-world data studies increased by 40%, supporting broader label expansions. Biosimilar development pipelines for MET inhibitors rose by 15%, reflecting competitive diversification in the C-MET & HGF Inhibitors Industry Analysis landscape.

Download Free Sample to learn more about this report

C-MET & HGF INHIBITORS MARKET SEGMENTATION

By Type Analysis

According to type, the market can be segmented into Cabozantinib, Crizotinib, Others. 

• Cabozantinib : Cabozantinib holds approximately 38% of the C-MET & HGF Inhibitors Market Share due to its multi-kinase inhibition profile targeting MET, VEGFR, and AXL pathways. It is approved in more than 60 countries and prescribed in 45% of advanced renal cell carcinoma cases requiring second-line therapy. Around 30% of hepatocellular carcinoma patients eligible for targeted therapy receive cabozantinib. Clinical data from over 2,000 patients support its efficacy, with progression-free survival improvements observed in 55% of treated populations.

• Crizotinib : Crizotinib accounts for nearly 27% of the C-MET & HGF Inhibitors Market Size. It is utilized in 3%–4% of NSCLC cases harboring MET alterations. Over 1,500 oncology centers globally prescribe crizotinib. Approximately 60% of eligible ALK-positive patients initially receive crizotinib therapy. Its global presence spans 70+ countries, and 40% of treated patients demonstrate measurable tumor shrinkage within 12 weeks.

• Others : Other MET inhibitors collectively represent 35% of the C-MET & HGF Inhibitors Market Growth, including selective MET inhibitors and investigational agents. Over 25 pipeline drugs are in Phase II or Phase III development. Around 15% of gastric cancer patients with MET amplification are enrolled in targeted therapy trials. These emerging therapies contribute to 20% expansion in treatment options between 2021 and 2024.

By Application Analysis

Based on application, the market can be divided into Hospital, Drug Store. Hospital will be dominating segment.

• Hospital : Hospitals contribute approximately 72% of total distribution in the C-MET & HGF Inhibitors Market Analysis. Over 80% of oncology infusions occur in hospital-based cancer centers. Around 65% of genomic testing laboratories are hospital-affiliated. More than 50% of advanced-stage cancer patients initiate therapy in tertiary care hospitals, reinforcing hospital dominance in prescription volume.

• Drug Store : Drug stores account for 28% of the C-MET & HGF Inhibitors Market Share. Nearly 40% of oral targeted therapy refills occur through specialty pharmacies. Around 35% of maintenance therapy patients rely on retail pharmacy networks. Over 20,000 specialty pharmacies globally dispense oncology medications, supporting outpatient treatment accessibility.

DRIVING FACTORS

Rising demand for precision oncology

The increasing burden of cancer, with 19.9 million new cases globally in 2023, directly drives the C-MET & HGF Inhibitors Market Growth. Approximately 85% of lung cancer cases are NSCLC, and 3%–4% of these involve MET exon 14 mutations. Molecular diagnostics adoption surpassed 60% in developed regions, increasing identification rates of MET alterations by 45% over 5 years. Around 58% of oncology treatment protocols now incorporate biomarker-based therapy selection. Over 100 ongoing clinical trials target MET-driven malignancies, reflecting strong innovation momentum in the C-MET & HGF Inhibitors Market Outlook.

RESTRAINING FACTORS

High adverse event rates and therapy costs

Adverse events such as edema and hepatotoxicity affect nearly 25%–30% of treated patients, limiting therapy continuation. Around 35% of healthcare systems in emerging markets lack advanced genomic testing facilities. Only 40% of patients in low-income regions receive comprehensive molecular diagnostics. Treatment discontinuation rates exceed 20% in certain patient populations. These factors create variability in treatment uptake and moderate the C-MET & HGF Inhibitors Market Size expansion across 50+ lower-middle-income countries.

Growth in personalized medicines

Opportunity

Personalized oncology penetration reached 55% in advanced cancer treatment regimens by 2024. Approximately 70% of oncology clinical pipelines involve targeted therapies. Over 25 biomarker-guided studies focus specifically on MET alterations. Asia-Pacific recorded a 60% increase in genomic testing capacity between 2020 and 2024. With 10% of gastric cancers exhibiting MET amplification, expanding indications create strong C-MET & HGF Inhibitors Market Opportunities across solid tumor segments.

Regulatory and clinical trial complexities.

Challenge

Regulatory approval timelines average 18–24 months for targeted oncology drugs. Nearly 30% of Phase III oncology trials face delays due to patient recruitment challenges. Over 45% of trials require companion diagnostic co-approval. Stringent safety monitoring increases development costs by 20%. These complexities influence pipeline progression and competitive positioning in the C-MET & HGF Inhibitors Industry Report landscape.

• Download Free Sample to learn more about this report

•  

C-MET & HGF INHIBITORS MARKET REGIONAL INSIGHTS

During the projection period, North America will dominate the global market

• North America

North America continues to maintain a dominant position in the C-MET & HGF Inhibitors Market due to advanced oncology infrastructure and high utilization of targeted therapies. In 2023, North America accounted for approximately 42%–44% of global oncology therapeutic adoption, with the United States reporting over 1.9 million new cancer diagnoses annually and lung cancer comprising roughly 12.4% of total cases. Molecular diagnostics are extensively integrated, with an estimated 65%–70% of cancer patients undergoing biomarker testing, including next-generation sequencing and liquid biopsy platforms. This broad testing landscape enhances identification of MET gene alterations, which are present in about 3%–4% of NSCLC (non-small cell lung cancer) patients.Precision oncology programs in the region report that more than 60% of eligible patients receive targeted treatment selection based on genomic profiling data, supporting early use of c-MET inhibitors in clinical protocols. More than 50 active clinical trials evaluating MET and HGF targeted agents are conducted across 10+ U.S. states. Canada contributes with over 230,000 cancer cases annually, and robust oncology research participation, especially in MET-driven malignancies. Biomarker research investment reflects that over 58% of diagnostic labs in major centers have implemented advanced MET testing capabilities.

• Europe

Europe is a key contributor to the C-MET & HGF Inhibitors Market, driven by widespread precision oncology adoption and strong public healthcare systems that support advanced diagnostics. Across 4.4 million new cancer cases reported in Europe in 2020, lung cancer constituted approximately 12.3% of diagnoses, making oncology a high-priority treatment segment. Biomarker testing penetration across Western Europe exceeds 55%, with countries such as Germany, France, the United Kingdom, Italy and Spain collectively representing over 60% of European targeted therapy utilization. European oncology centers are increasingly incorporating MET and genomic profiling technologies, particularly in Germany where advanced academic research infrastructure supports over 30 national precision medicine programs. Multi-gene panels and molecular profiling platforms are available in roughly 58% of major cancer treatment facilities, enhancing the detection of MET exon 14 skipping mutations and MET amplification events that occur in 5%–10% of specific tumor types such as papillary renal carcinoma and NSCLC.

• Asia-Pacific

Asia-Pacific represents one of the fastest growing regions for C-MET & HGF Inhibitors Market activity due to high cancer incidence and rapidly expanding diagnostic capacity. In 2020, China alone reported 4.6 million new cancer cases, accounting for nearly 24% of global incidence, while India recorded over 1.4 million. Japan reported more than 1 million cancer diagnoses annually. Across these geographies, precision oncology adoption has gained traction, with molecular testing volumes increasing by approximately 50% over recent years. In China, expanded national cancer screening programs and genomic profiling have contributed to a 55% rise in advanced diagnostics usage, particularly for actionable mutations such as MET exon 14 skipping variants. Japan implemented reimbursement adjustments that increased multi-gene panel utilization by nearly 38%, enabling broader detection of MET alterations among lung cancer patients, where EGFR and other mutations also exhibit high prevalence. India’s biomarker testing adoption grew by nearly 49%, though rural and resource-limited areas still lag in access. Asia-Pacific now contributes over 22% of global molecular diagnostic testing volumes, supporting identification of MET mutations that impact approximately 3%–4% of NSCLC patients and 10% of papillary renal carcinoma patients. Cross-country collaborations and government cancer research initiatives have expanded clinical trial enrollment by 35% over the past 3 years, with Singapore, Thailand and Malaysia emerging as regional clinical research hubs.

• Middle East & Africa

The Middle East & Africa’s contribution to the C-MET & HGF Inhibitors Market reflects a growing but still emergent oncology landscape, shaped by investment in healthcare infrastructure and rising cancer incidence. The region recorded over 1.1 million new cancer cases in 2020, with breast cancer representing nearly 19% of diagnoses, followed by prostate, lung, and colorectal cancers in significant proportions. Although advanced molecular diagnostics infrastructure remains limited compared with Western regions, adoption is improving: biomarker testing penetration has expanded by over 29% as health systems modernize. Saudi Arabia and the United Arab Emirates are leading regional investments, with both countries bolstering precision oncology capabilities and genomic testing awareness. South Africa accounts for a substantial share of Sub-Saharan oncology activity, reporting over 108,000 cancer diagnoses annually and rising lung cancer cases due to tobacco use and environmental factors. Egypt also contributes notably with 134,632 new cancer cases reported, reflecting expanding oncology intervention requirements. Liquid biopsy adoption in MEA has increased by nearly 31%, and multi-gene panel utilization improved by 27% across major oncology centers. These diagnostic enhancements support identification of key oncogenic drivers such as MET alterations in NSCLC and other solid tumors, albeit at lower absolute volumes compared to North America and Europe. Partnerships between local health ministries and international pharmaceutical sponsors have led to more than 10 multinational clinical trials being initiated in the region, expanding access to c-MET & HGF targeted agents.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

LIST OF TOP C-MET & HGF INHIBITORS COMPANIES​​​​​​​

•  Bristol-Myers Squibb(BMS)
• Takeda
• Roche
• Daiichi Sankyo
• Mirati Therapeutics
• Pfizer
• Merck KGaA
• AstraZeneca
• Novartis
• GSK
• Eisai
• Johnson & Johnson
• Merck
• Kringle Pharmaceuticals
• Exelixis
• Amgen
• AVEO Pharmaceuticals
• Ipsen
• Hutchison MediPharma
• Eli Lilly

Top 2 Companies with Highest Market Share:

Exelixis holds approximately 24% market share driven by cabozantinib adoption in over 60 countries, while Pfizer accounts for nearly 18% share supported by crizotinib distribution across 70+ countries and utilization in 60% of eligible ALK-positive NSCLC patients.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Global oncology R&D spending exceeded $90 billion in 2024, with approximately 35% allocated to targeted therapies. Over 120 MET-focused clinical trials were active globally. Venture funding in oncology biotech increased by 28% between 2022 and 2024. Around 40% of biotech IPOs in 2023 focused on precision medicine. Asia-Pacific governments allocated 15% higher budgets toward cancer genomic infrastructure. Strategic collaborations increased by 32% year-over-year, with over 25 licensing agreements signed for MET inhibitors. These factors expand C-MET & HGF Inhibitors Market Opportunities across 30+ oncology segments.

NEW PRODUCT DEVELOPMENT

Between 2023 and 2025, more than 10 new MET-targeted molecules entered Phase I trials. Approximately 6 drugs advanced to Phase III evaluation. Dual-target inhibitors addressing MET and VEGFR pathways increased by 45% in pipeline composition. Over 20 biomarker-driven companion diagnostics were co-developed. Nanoparticle-based delivery systems improved drug bioavailability by 25% in early-stage trials. Around 55% of pipeline candidates focus on combination regimens. AI-driven drug discovery reduced preclinical screening time by 30%, accelerating C-MET & HGF Inhibitors Market Growth through innovation.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, 2 Phase III MET inhibitor trials enrolled over 800 patients each across 15 countries.
• In 2024, 3 expanded indication approvals were granted covering 5 additional tumor types.
• In 2024, molecular testing rates increased by 40% in Asia-Pacific clinical networks.
• In 2025, 4 combination therapy trials reported over 50% objective response rates.
• Between 2023 and 2025, 12 strategic partnerships were signed targeting 20 new oncology centers.

REPORT COVERAGE

The C-MET & HGF Inhibitors Market Report covers analysis across 4 regions, 20 leading companies, and 3 product types. The C-MET & HGF Inhibitors Industry Report evaluates over 120 clinical trials, 25 pipeline drugs, and 50 regulatory approvals. It includes data from 2019 to 2025, covering 70+ countries and 2 major application segments. The C-MET & HGF Inhibitors Market Research Report provides insights into 38% cabozantinib share, 27% crizotinib share, and 72% hospital distribution dominance. Over 200 data points related to molecular testing rates, mutation prevalence, and patient volumes are analyzed, delivering detailed C-MET & HGF Inhibitors Market Insights for B2B stakeholders seeking strategic expansion.